- Home
- INVE vs APLT Comparison
INVE vs APLT Comparison
Compare INVE & APLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INVE
- APLT
- Stock Information
- Founded
- INVE 1990
- APLT 2016
- Country
- INVE United States
- APLT United States
- Employees
- INVE N/A
- APLT N/A
- Industry
- INVE Computer peripheral equipment
- APLT Biotechnology: Pharmaceutical Preparations
- Sector
- INVE Technology
- APLT Health Care
- Exchange
- INVE Nasdaq
- APLT Nasdaq
- Market Cap
- INVE 74.2M
- APLT 52.9M
- IPO Year
- INVE 1997
- APLT 2019
- Fundamental
- Price
- INVE $3.24
- APLT $0.33
- Analyst Decision
- INVE Strong Buy
- APLT Buy
- Analyst Count
- INVE 3
- APLT 7
- Target Price
- INVE $6.50
- APLT $6.10
- AVG Volume (30 Days)
- INVE 72.1K
- APLT 2.3M
- Earning Date
- INVE 08-07-2025
- APLT 08-06-2025
- Dividend Yield
- INVE N/A
- APLT N/A
- EPS Growth
- INVE N/A
- APLT N/A
- EPS
- INVE 3.12
- APLT N/A
- Revenue
- INVE $25,239,000.00
- APLT $265,000.00
- Revenue This Year
- INVE N/A
- APLT $1,768.13
- Revenue Next Year
- INVE $9.00
- APLT $292.85
- P/E Ratio
- INVE $1.04
- APLT N/A
- Revenue Growth
- INVE N/A
- APLT N/A
- 52 Week Low
- INVE $2.86
- APLT $0.30
- 52 Week High
- INVE $4.35
- APLT $10.62
- Technical
- Relative Strength Index (RSI)
- INVE 49.66
- APLT 43.25
- Support Level
- INVE $3.10
- APLT $0.30
- Resistance Level
- INVE $3.25
- APLT $0.36
- Average True Range (ATR)
- INVE 0.11
- APLT 0.03
- MACD
- INVE -0.00
- APLT -0.00
- Stochastic Oscillator
- INVE 55.00
- APLT 22.22
About INVE Identiv Inc.
Identiv Inc is a security technology company. It secures and manages access to physical places, things, and information. The company has one reportable segment: the IoT Business segment. Geographically, it generates maximum revenue from the Americas and also has a presence in Europe and the Middle East, and Asia-Pacific.
About APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.